Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...340341342343344345346347348349350...10671068»
  • ||||||||||  dexamethasone / Generic mfg.
    Endogenous Fatty Acid Derivatives Prevent Maternal Stress Induced Preterm Birth in Mice. () -  Apr 6, 2022 - Abstract #SRI2022SRI_637;    
    Our results indicate that 15-PGJ2 or 9N or 10N inhibits Dex-induced FKBP51 levels and prevents maternal stress-induced PTB in mice, prolonging gestation to the length observed in control mice. These findings support use of these agents in preclinical and clinical trials as novel therapeutics to prevent or delay idiopathic PTB.
  • ||||||||||  dexamethasone / Generic mfg.
    Glucocorticoid Signaling Critically Mediates Human Endometrial Stromal Cell Decidualization. () -  Apr 6, 2022 - Abstract #SRI2022SRI_629;    
    To identify glucocorticoid target genes, primary human endometrial stromal cells (ESC) were treated for 6 hours with glucocorticoids (100nM dexamethasone)... These studies demonstrate that physiological uterine glucocorticoid signaling is required for the critical first steps of pregnancy in human endometrial stromal cells by regulating the expression of key target genes.
  • ||||||||||  dexamethasone / Generic mfg.
    Regulation of Placental Neonatal Fc Receptor by Hormones During Pregnancy. () -  Apr 6, 2022 - Abstract #SRI2022SRI_505;    
    DEX and P4, both increased at the end of pregnancy, lead to better binding capacities and higher mRNA expression. The male sex hormone and other substances correlating with TT in cord blood may as well play an important role in FcRn regulation and may be responsible for declined transport properties of the placental Ig-transporter.
  • ||||||||||  hydrocortisone / Generic mfg.
    Identification of FOXC1 as a Key Transcriptional Regulator in Endometriotic Lesions. () -  Apr 6, 2022 - Abstract #SRI2022SRI_115;    
    Further, combined transcriptomic analyses identified FOXC1 as an upstream transcription factor andIL6 as a central cytokine in inflammatory pathways. Increased IL6 in endometriotic stromal cells has been hypothesized to play a key role in lesion pathophysiology by affecting immune cells and local inflammatory signaling.
  • ||||||||||  dexamethasone / Generic mfg.
    Trial completion date, Trial primary completion date:  Preoperative High-dose Dexamethasone and Emergency Laparotomy (clinicaltrials.gov) -  Apr 6, 2022   
    P4,  N=110, Recruiting, 
    N=270 --> 396 Trial completion date: Jun 2022 --> Nov 2022 | Trial primary completion date: Jan 2022 --> Aug 2022
  • ||||||||||  budesonide / Generic mfg.
    Review, Journal:  Current treatment of IgA nephropathy. (Pubmed Central) -  Apr 5, 2022   
    Beyond corticosteroids, there is little evidence that any additional immunosuppression is helpful, with the exception of mycophenolate mofetil in patients of Asian descent. A considerable number of clinical trials ranging from enteric coated budesonide to blockade of B-cell function to complement inhibitors are currently ongoing and will hopefully allow a more targeted therapy of high-risk patients with progressive IgAN in the future.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Possible harm from glucocorticoid drugs misuse in the early phase of SARS-CoV-2 infection: a narrative review of the evidence. (Pubmed Central) -  Apr 5, 2022   
    However, the benefit of dexamethasone was largest in patients who received mechanical ventilation or supplemental oxygen therapy, while no benefit was found among patients without hypoxemia...The GC misuse can lead to a more severe disease even in patients who do not have the established risk factors, such as obesity and cardiovascular diseases. In our focused review, we describe the role of immune response in viral infections, especially SARS-CoV-2, and discuss the potential harms of GC misuse in COVID-19.
  • ||||||||||  Sarclisa (isatuximab-irfc) / Sanofi
    Journal:  Isatuximab: Nursing Considerations for Use in the Treatment of Multiple Myeloma. (Pubmed Central) -  Apr 5, 2022   
    P3
    Nursing care of patients prescribed isatuximab includes monitoring of clinical and laboratory parameters and requires knowledge and management of associated adverse events, including infusion reactions and neutropenia. This information could aid oncology nurses in providing optimal, treatment-specific education to patients and caregivers.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Early localized Vitiligo, a medical emergency: long term follow up study. (Pubmed Central) -  Apr 5, 2022   
    Early systemic immunomodulation for recent localized vitiligo is a successful approach to achieve early control of disease activity and minimize the incidence of recurrence. Such cases should not be overlooked but managed as early as possible; it is a race against time.
  • ||||||||||  dexamethasone / Generic mfg., methotrexate IV / Generic mfg., methotrexate / Generic mfg.
    Clinical, PK/PD data, Review:  A Systematic Review of Population Pharmacokinetic Models of Methotrexate. (Pubmed Central) -  Apr 5, 2022   
    Various covariates could affect MTX pharmacokinetics, and their relationships have been summarized and discussed. This review will be helpful for researchers to develop their own population pharmacokinetic models and select appropriate models for individualized therapy of MTX.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. (Pubmed Central) -  Apr 5, 2022   
    Currently, there is no effective drugs for treating clinically COVID-19 except dexamethasone...In addition, lymphocytes recovered more quickly in hymecromone-treated patients (n = 8) than control group (n = 5) (P < 0.05). These findings suggest that hymecromone is a promising drug for COVID-19 and deserves our further efforts to determine its effect in a larger cohort.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Pharmacologically Enhanced Regulatory Hematopoietic Stem Cells Revert Experimental Autoimmune Diabetes and Mitigate Other Autoimmune Disorders. (Pubmed Central) -  Apr 5, 2022   
    A high-throughput targeted RNA sequencing screening strategy was used to identify a combination of small molecules (16,16-dimethyl PGE and dexamethasone), which significantly upregulate key genes involved in trafficking (e.g., CXCR4) and immunoregulation (e.g., programmed death ligand 1)...Moreover, when tested in clinically relevant in vitro autoimmune assays, HSC.Regs abrogated the autoimmune response. Ex vivo pharmacological modulation enhances the immunoregulatory and trafficking properties of HSCs, thus generating HSC.Regs, which mitigated autoimmune diabetes and other autoimmune disorders.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  Tocilizumab for treatment of SARS-CoV-2 infection at home: A case report. (Pubmed Central) -  Apr 5, 2022   
    SARS-CoV-2 virtual wards have successfully developed to monitor and escalate patients to hospital throughout the pandemic. Here we describe the case of an 84 year old man who received his complete care for severe SARS-CoV-2 pneumonitis at home, including the administration of oxygen, dexamethasone and tocilizumab.
  • ||||||||||  dexamethasone / Generic mfg.
    Journal:  Corticosteroid suppresses urea-cycle-related gene expressions in ornithine transcarbamylase deficiency. (Pubmed Central) -  Apr 5, 2022   
    We elucidated that corticosteroid administration induced hyperammonemia in Otc mice by not only muscle catabolism but also suppressing urea-cycle-related gene expressions. Since the urea cycle intermediate amino acids, such as arginine, might not be effective because of the suppressed expression of urea-cycle-related genes by corticosteroid administration, we should consider an early intervention by renal replacement therapy in cases of UCD patients induced by corticosteroids to avoid brain injuries or fatal outcomes.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Retrospective data, Journal:  C-reactive protein cut-off for early tocilizumab and dexamethasone prescription in hospitalized patients with COVID-19. (Pubmed Central) -  Apr 5, 2022   
    Multivariate analysis identified the interaction of CRP > 13.75 mg/dL with dexamethasone (OR 0.57; CI 95% 0.37-0.89, P = 0014) and CRP > 3.5 mg/dL with tocilizumab (0.65; CI95%:0.44-0.95, P = 0.029) as independent predictors of mortality. Our results suggest that dexamethasone and tocilizumab are associated with a reduction in mortality when prescribed to patients with a certain inflammatory activity assessed by C-reactive protein.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Journal:  Increased angiogenic factors in the aqueous and vitreous humors after disinsertion of extraocular muscle and the effects of triamcinolone acetate injection. (Pubmed Central) -  Apr 5, 2022   
    Subconjunctival injection of triamcinolone acetonide (TA) was administered and three cytokine concentrations in the aqueous humor and vitreous humor were measured at 12 h after TA injection...The aqueous and vitreous humor concentrations of VEGF in eyes with simultaneous TA injection were significantly lower than were those in the ASI group (p = 0.02, all). The concentration of PGE2, HIF-1α, and VEGF in the aqueous humor was increased after induction of ASI and TA injection seems to be effective in inhibiting VEGF elevation in ASI.